Doer Bio and MSD Collaborate on Clinical Trial for Anti-Claudin18.2 Antibody DR30303
China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US...
PD-1/L1
Tracon Pharmaceuticals Provides Positive Update on Envafolimab Phase II Trial
China-based Alphamab Oncology (HKG: 9966)’s US partner Tracon Pharmaceuticals (NASDAQ: TCON) has provided an early...
Henlius Biotech Initiates Phase I Trial for HLX60 in Australia
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...
ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...
Alphamab Oncology Updates Clinical Studies for KN046 and KN026 at SABCS 2022
China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at...
Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199
Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based...
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...
Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics
A new bar was set for the most valuable out-license deal struck by a China-based...
Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...
Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study
China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...
Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...
Eli Lilly Ends License for Innovent’s Tyvyt Outside China
Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...
Henlius Completes First Dosing in Head-to-Head Study of PD-1 Inhibitor HanSiZhuang
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...
Junshi Biosciences Files for UK Approval of PD-1 Inhibitor Tuoyi
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has filed for market...
Aosaikang’s ASKG915 Accepted for FDA Review, Targets Advanced Solid Tumors
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that its clinical trial filing for...
Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug...
Akeso Biopharma’s AK112 Receives Two New Breakthrough Therapy Designations
The Center for Drug Evaluation (CDE) website indicates that China-based Akeso Biopharma (HKG: 9926) has...
EQRx Shifts Strategy Amid FDA Feedback on China-Sourced Data
US-based EQRx Inc. (Nasdaq: EQRX), a biopharma originally established with the aim of “radically” disrupting...
CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study
China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...